SEL + FIR + CILO + Placebo to match FIR + Placebo to match CILO + Placebo to match SEL
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Nonalcoholic Steatohepatitis
Conditions
Nonalcoholic Steatohepatitis
Trial Timeline
Mar 21, 2018 → Nov 19, 2019
NCT ID
NCT03449446About SEL + FIR + CILO + Placebo to match FIR + Placebo to match CILO + Placebo to match SEL
SEL + FIR + CILO + Placebo to match FIR + Placebo to match CILO + Placebo to match SEL is a phase 2 stage product being developed by Gilead Sciences for Nonalcoholic Steatohepatitis. The current trial status is completed. This product is registered under clinical trial identifier NCT03449446. Target conditions include Nonalcoholic Steatohepatitis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03449446 | Phase 2 | Completed |
Competing Products
20 competing products in Nonalcoholic Steatohepatitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| VK2809 + Placebos | Viking Therapeutics | Phase 2 | 47 |
| TERN-501 + TERN-101 | Terns Pharmaceuticals | Phase 2 | 49 |
| TERN-101 | Terns Pharmaceuticals | Phase 2 | 49 |
| TERN-201 | Terns Pharmaceuticals | Phase 1 | 30 |
| Lanifibranor | Inventiva | Phase 2 | 47 |
| IVA337 + Placebo + Empagliflozin | Inventiva | Phase 2 | 47 |
| IVA337 + Placebo | Inventiva | Phase 3 | 72 |
| Colesevelam Hcl | Daiichi Sankyo | Phase 2 | 52 |
| Tirzepatide + Placebo | Eli Lilly | Phase 2 | 52 |
| AZD2693 | AstraZeneca | Phase 2 | 52 |
| Roflumilast + Pioglitazone + Placebo + Placebo | AstraZeneca | Phase 2 | 52 |
| MK-3655 + Placebo | Merck | Phase 2 | 52 |
| Efinopegdutide 20 mg/mL + Semaglutide 1.34 mg/mL | Merck | Phase 2 | 52 |
| SEL + Placebo to match SEL 6 mg + Placebo to match SEL 18 mg | Gilead Sciences | Phase 3 | 76 |
| Seladelpar + Placebos | Gilead Sciences | Phase 2 | 51 |
| Cilofexor | Gilead Sciences | Phase 1 | 32 |
| Firsocostat + Fenofibrate | Gilead Sciences | Phase 1 | 32 |
| GS-9674 + Placebo to match GS-9674 | Gilead Sciences | Phase 2 | 51 |
| GS-9450 + GS-9450 Placebo | Gilead Sciences | Phase 2 | 51 |
| Semaglutide + Firsocostat + Cilofexor | Gilead Sciences | Phase 2 | 51 |